# AZAFAROS B.V.: Research, Naarden, Netherlands

> AZAFAROS B.V.: AZAFAROS B.V. is a clinical-stage biotechnology company founded in 2018, based in Naarden, Netherlands, with operations in Leiden and Basel...

Source: https://millionrounds.com/startup/azafaros-b-v (Millionrounds; every figure on the page links to its filing or article)

Netherlands · [Research startup](https://millionrounds.com/companies)

# AZAFAROS B.V.

AZAFAROS B.V. is a clinical-stage biotechnology company founded in 2018, based in Naarden, Netherlands, with operations in Leiden and Basel, Switzerland.

Funding reported Last round: Series B

Research Naarden, Netherlands

Company summary

- **Founded:** 2018 8 years old
- **Team:** 34 11 to 50 people
- **Funding reported:** 175M as listed, currency not stated
- **Last round:** Series B May 2025

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for AZAFAROS B.V. has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About AZAFAROS B.V.

AZAFAROS B.V. is a clinical-stage biotechnology company founded in 2018, based in Naarden, Netherlands, with operations in Leiden and Basel, Switzerland.

The company specializes in developing oral, disease-modifying small molecule therapeutics for patients with severe rare genetic lysosomal storage disorders that affect the central nervous system. Led by a team of experienced industry professionals, AZAFAROS aims to create new treatment options for life-threatening metabolic conditions where effective therapies are currently lacking. The company's lead clinical-stage program, Nizubaglustat (also known as AZ-3102), is an orally available small molecule that targets key disease pathways by interfering with glycosphingolipid metabolism. It is designed to treat conditions such as GM1 and GM2 gangliosidoses and Niemann-Pick disease type C. AZAFAROS is committed to patient-centric innovation, focusing on rapidly developing therapeutics for rare diseases and translating academic research into commercial solutions.

## What company datasets say AZAFAROS B.V. raised

Funding, as reported

Reported in all **175M** in the source's currency

Last round **Series B**

Last round size **145.2M**

Last round date **May 2025**

Investors listed **5**

## Founders and team

From AZAFAROS B.V.'s own website: 3 on the team.

- **Amy Sullivan** Chief Financial Officer
- **Dominique Nijkamp** Chief Clinical Development Officer
- **Gisela Linthorst** Head of Patient Engagement and Advocacy

## On 3 portfolio pages

Investors who name them

- [Seroba.](https://millionrounds.com/fund/seroba)
- [Jeito Capital](https://millionrounds.com/fund/jeito-capital)
- [Seroba Life Sciences](https://millionrounds.com/fund/seroba-life-sciences)

Each firm lists AZAFAROS B.V. on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

patient-centered approach health care disease pathways metabolic pathway targeting patient resource development biotechnology research disease pathway modulation pharmaceutical development disease-modifying therapeutics neurodegenerative diseases genetic mutations glycosphingolipid metabolism regulatory approvals small molecule drugs niemann-pick disease type c patient advocacy

Built with from their website

Google Tag Manager Google Font API LiteSpeed HSTS HREF Lang Microsoft Exchange Microsoft 365 Font Awesome Outlook reCAPTCHA

+8 more

Microsoft 365 Apps & Services Viewport Meta Mobile Friendly Multilingual Microsoft Email Providers Open Graph Brevo Microsoft Exchange Online

- **Sector:** Research
- **Industry code:** NAICS 32541, 541714, SIC 2834
- **Region:** North Holland
- **Revenue:** 60M a year, as listed

## Research in Netherlands

Startups like it

- [**Citryll** Oss · founded 2015 *Raised*](https://millionrounds.com/company/citryll)
- [**Leyden Labs** Leiden · founded 2020 *Raised*](https://millionrounds.com/company/leyden-labs)
- [**NorthSea Therapeutics** Amsterdam · founded 2017 *Raised*](https://millionrounds.com/company/northsea-therapeutics)
- [**Synerkine Pharma** Leiden · founded 2018 *Raised*](https://millionrounds.com/company/synerkine-pharma)
- [**ENPICOM** 's-Hertogenbosch · founded 2015 *Raised*](https://millionrounds.com/company/enpicom)
- [**PHOSPHOENIX** Amsterdam · founded 2019 *Raised*](https://millionrounds.com/company/phosphoenix)
- [**VectorY** Amsterdam · founded 2020](https://millionrounds.com/startup/vectory)
- [**Ambagon Therapeutics** Eindhoven · founded 2020](https://millionrounds.com/startup/ambagon-therapeutics)

## Is this your company?

Add your raise, your deck and your story, and put AZAFAROS B.V. in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)